Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 127.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 137.50
  • 52 Week Low: 96.00
  • Currency: UK Pounds
  • Shares Issued: 104.77m
  • Volume: 5,203
  • Market Cap: £133.58m
  • RiskGrade: 80
  • Beta: 0.10

Cello Health reports positive momentum as it works on US market

By Josh White

Date: Wednesday 18 Sep 2019

LONDON (ShareCast) - (Sharecast News) - Healthcare-focussed advisory firm Cello Health reported a 6.8% improvement in net revenue to £54.5m in its half-year results on Wednesday, with its like-for-like constant currency net revenue growth standing at 4.5%.
The AIM-traded company said Cello Health divisional net revenue growth was 11.6%, with like-for-like constant currency growth there being 8.2%.

Cello Signal divisional net revenue declined 0.1%, however, with like-for-like constant currency revenue in that division declining 1.0%.

The firm's headline profit before tax was ahead 12.7% year-on-year for the six months ended 30 June to £5.7m, while its headline operating margin improved to 10.9%, from 10.4% a year earlier.

Headline basic earnings per share were 12.7% higher at 4.08p, compared to 3.62p last year.

On a statutory basis, profit before tax was 39.7% higher at £4.7m, and basic earnings per share rose 40.3% to 3.31p.

The board reported "strong" cash flow for the period, with net funds as at 30 June standing at £2.2m, swinging from net debt of £5.4m a year prior.

It declared a 4.5% improvement to the interim dividend, to 1.15p.

On the operational front, Cello described "strong" growth across Cello Health, particularly in the United States, and added that its new Berlin office was now fully servicing European clients.

It added that the acquisition of ISS in August, post period end, further strengthened Cello Health's US advisory capability.

"The first half of 2019 has continued to see strong growth from Cello Health, notably in the US market," said chief executive officer Mark Scott.

"Cello Health Communications and Cello Health Consulting have made particularly pleasing progress."

Scott said the addition of ISS in August would help contribute to that momentum, and had added "critical" regulatory expertise.

"Good revenue visibility for the remainder of the year gives us confidence for a strong full year outcome."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 127.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 137.50
52 Week Low 96.00
Volume 5,203
Shares Issued 104.77m
Market Cap £133.58m
Beta 0.10
RiskGrade 80

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
66.8% below the market average66.8% below the market average66.8% below the market average66.8% below the market average66.8% below the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average
Price Trend
10.97% below the market average10.97% below the market average10.97% below the market average10.97% below the market average10.97% below the market average
15% below the sector average15% below the sector average15% below the sector average15% below the sector average15% below the sector average
Income
7.96% above the market average7.96% above the market average7.96% above the market average7.96% above the market average7.96% above the market average
57.14% above the sector average57.14% above the sector average57.14% above the sector average57.14% above the sector average57.14% above the sector average
Growth
32.55% below the market average32.55% below the market average32.55% below the market average32.55% below the market average32.55% below the market average
41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Interim Final
Ex-Div 03-Oct-19 25-Apr-19
Paid 01-Nov-19 24-May-19
Amount 1.15p 2.75p

Trades for 18-Oct-2019

Time Volume / Share Price
14:15 41 @ 126.26p
10:11 5,162 @ 126.80p

Cello Health Key Personnel

CEO Mark Scott

Top of Page